赛马鲁肽
医学
炎症性肠病
减肥
肥胖
胃肠病学
疾病
克罗恩病
内科学
内分泌学
糖尿病
2型糖尿病
利拉鲁肽
作者
Aakash Desai,Himsikhar Khataniar,Jana G. Hashash,Francis A. Farraye,Miguel Regueiro,Gursimran Kochhar
出处
期刊:Inflammatory Bowel Diseases
[Oxford University Press]
日期:2024-04-20
被引量:4
摘要
Semaglutide, a glucagon-like peptide-1 receptor agonist, has shown sustained and clinically significant weight loss in the general population. There are limited data on outcomes of its use in patients with inflammatory bowel disease (IBD).
科研通智能强力驱动
Strongly Powered by AbleSci AI